

Charity registration number 1137689 (England and Wales)

Charity registration number SC049777 (Scotland)

Company registration number 07272699 (England and Wales)

PANCREATIC CANCER ACTION
ANNUAL REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

PANCREATIC CANCER ACTION

LEGAL AND ADMINISTRATIVE INFORMATION

Trustees	N Menezes
	R Legg
	C Carter
	E Cowan
	N Longworth
	L Nylander
	G Codacci Pisanelli (Appointed 18 March 2024)
	D Slater (Appointed 18 March 2024)
	G Lesca (Appointed 18 March 2024)
Secretary	G Brown (Resigned 12 January 2023)
Charity number (England and Wales)	1137689
Charity number (Scotland)	SC049777
Company number	07272699
Registered office	BASE Bordon Innovation Centre Broxhead House 60 Barbados Road Bordon GU35 0FX
Auditor	Alliotts LLP 3 London Square Cross Lanes Guildford GU1 1UJ

PANCREATIC CANCER ACTION

CONTENTS

	Page
CEO's report	1
Trustees' report	2 - 8
Independent auditor's report	9 - 11
Statement of financial activities	12
Balance sheet	13
Statement of cash flows	17
Notes to the financial statements	14 - 26

PANCREATIC CANCER ACTION

CEO'S REPORT

FOR THE YEAR ENDED 31 DECEMBER 2023

The year 2023 was one of change and growth for Pancreatic Cancer Action while continuing to champion the voice of patients and families, support individuals in a time of crisis and campaign to improve early diagnosis and save lives.

During the year we welcomed a new Chief Executive for the first time in thirteen years, we delivered our largest-ever digital symptom awareness campaign, we supported a record number of patients and families, we rebuilt relationships with volunteers and our wider community and we delivered major system changes through our lobbying and campaign work.

We are rightly very proud of our achievements; however, we know that there is still a great deal of work remaining to be done if we are to improve pancreatic cancer survival rates and save lives. This means we will have to redouble our efforts in all areas if we are to finally improve the care for patients and get people diagnosed in time for life-saving surgery.

It is worth noting that as an organisation Pancreatic Cancer Action could not operate at the same level without the hard work and dedication of our volunteers. They fulfil such varied roles from campaigners and fundraisers to reviewing our patient information booklets and of course, serving on our Trustee Board or as Ambassadors. Without our volunteers, hardworking staff team, patients and families we could not do what we do.

Looking forward to 2024 we plan to build on that proud record of growth and activity we established in 2023. We shall do this through investing more in research, creating new resources to support patients, recruiting more volunteers, delivering innovative campaigns and promoting our resources for healthcare professionals.

We look forward to fighting for each and every patient and their families.


Joe Kirwin (Sep 6, 2024 11:19 GMT+1)

Joe Kirwin

Chief Executive

Dated: 06/09/2024.....

PANCREATIC CANCER ACTION

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) FOR THE YEAR ENDED 31 DECEMBER 2023

The Trustees present their annual report and financial statements for the year ended 31 December 2023.

The financial statements have been prepared in accordance with the accounting policies set out in note 1 to the financial statements and comply with the charity's Memorandum and Articles of Association, the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005, the Charities Accounts (Scotland) Regulations 2006 (as amended) and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)".

Objectives and activities

Our purpose

Pancreatic Cancer Action works to save lives through promoting earlier diagnosis of pancreatic cancer. We do this through promoting greater awareness of the symptoms of the disease, the funding and development of medical educational programmes, supporting patients through improved information about pancreatic cancer either on our website or in print and by funding research.

Our vision

Our vision is that everyone survives pancreatic cancer.

Our mission

Our mission is to improve survival rates of pancreatic cancer by ensuring more people are diagnosed early and that everyone has access to effective treatments, support, information and care.

Objectives

The charity's objectives are:

- A** **Awareness** - increase public awareness and knowledge of pancreatic cancer and its symptoms to achieve early diagnosis
- C** **Campaign** and lobby the government and key stakeholders for change to advance the standard of healthcare for individuals affected by pancreatic cancer
- T** **Train** and provide pioneering educational resources for our medical and healthcare communities
- I** **Innovative** research - we fund it, we support it - to improve early diagnosis and develop effective treatments to improve pancreatic cancer outcomes
- O** **Offer** the provision of practical and emotional support and information to all affected by pancreatic cancer
- N** **Now** – we are the action charity and action is needed more than ever before!

The Trustees have paid due regard to guidance issued by the Charity Commission in deciding what activities the charity should undertake.

The Trustees' activities

The Trustees meet regularly to develop and support strategies to meet the charitable objectives. The Trustees currently have a range of skills and experience that range from medical/scientific, legal, corporate governance, finance and PR.

Role of volunteers / PCA Action Ambassadors

The Charity receives the very welcome assistance of volunteers, who help support a range of projects to raise awareness of pancreatic cancer, provide support, review literature and fundraise in their communities.

The charity seeks volunteer assistance via the website, social media and by word of mouth.

Public benefit statement

The Trustees confirm that they have complied with the duty in Section 4 of the Charities Act 2011 to have due regard to the Charity Commission's general guidance on public benefit.

PANCREATIC CANCER ACTION

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

Achievements and performance

Using some of our objectives as headings and some other key areas not covered above, we have set out below highlights of activity and work in 2023 in our ongoing mission to improve survival rates of pancreatic cancer by ensuring more people are diagnosed early and that everyone has access to effective treatments, support, information and care.

1. Awareness - increase public awareness and knowledge of pancreatic cancer and its symptoms to achieve early diagnosis

Throughout the year Pancreatic Cancer Action provided individuals, communities and organisations with resources to help raise and improve symptom awareness of Britain's deadliest cancer. We did this through providing posters, leaflets, booklets, online resources, and occupational health talks. In our mission to improve early diagnosis and save lives, symptom awareness is key to ensuring that people approach their GP for support.

As well as providing these resources to individuals and communities free of charge, Pancreatic Cancer Action also took proactive and innovative steps to raise awareness with different communities and target those hard-to-reach groups. This included attending the **Health & Wellbeing at Work Show** on 14-15 March 2023 at the NEC Birmingham. This was an opportunity for us to promote our occupational health resources to organisations and companies both large and small. Cancer is a significant and growing issue in the workplace and it also has a significant impact on the economy. Issues like cancer can be very difficult to discuss in the workplace so through attending the Health & Wellbeing at Work Show we were able to educate employers about the need to properly support their employees who might have suspicions of cancer or are going through cancer treatment and just as importantly we were able to provide them with resources and an offer of occupational health training for their employees.

Following on from our success the previous year in reaching out to communities who do not have English as their first language, we took further steps to update our **translated online and print health education resources**. This meant we could provide quality accredited health information to those who have **Polish, Urdu, Punjabi, Bengali, Arabic or Gujarati** as their first language. These updates included highly trained medical professionals with their own first language experience reviewing the medical advice to ensure it was up to date and accurate.

Not being content with waiting for people with concerns to seek out support, as part of our ongoing **Action on the Ground** project we sought out communities with a low health literacy to provide them with symptom awareness resources. This included partnering with The Women's Integration Network in Glasgow to deliver an education talk and provide copies of a "Quick Guide to Pancreatic Cancer" in both Arabic and Urdu to the large number of non-native English speakers who are part of the Women's Integration Network. We also partnered with the Coalfields Regeneration Trust to specifically target men in former mining communities where health literacy is low. This partnership resulted in the production of symptom-awareness beer mats that were distributed to pubs and working men's clubs in areas of high deprivation.

The chance of developing pancreatic cancer unfortunately increases with age and therefore we must take action to reach out to educate older people on the symptoms of pancreatic cancer. One of the ways we did this in 2023 was sharing 10,000 symptom awareness leaflets at Gardeners World Live. The demographics of those who attend this event skew older and are more likely to need this essential information that could save their lives. We also visited a number of older people's groups to deliver symptom awareness talks and provide leaflets to them.

Pancreatic Cancer Awareness Month or PCAM in November is normally our best opportunity to get key health information out there to the public and improve symptom awareness. 2023 was the **biggest digital symptom awareness campaign** ever delivered by Pancreatic Cancer Action. We reached more people than ever before through our innovative and groundbreaking **#missed** campaign. Through the hashtag missed campaign, we sought to highlight all those who passed away from pancreatic cancer because their symptoms were missed. These symptoms were either missed by healthcare professionals or by the individuals themselves.

Collaborative campaigns with **Purple Lights UK** and **The World Pancreatic Cancer Coalition** continue to see locations across the world light up purple to raise awareness during November and in particular on **World Pancreatic Cancer Day**. This is largely a supporter focused campaign and has evolved to include supporters lighting up their towns in support, as well as buildings and landmarks.

PANCREATIC CANCER ACTION

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

Pancreatic Cancer Action had a presence at Glasgow Central Station on World Pancreatic Cancer Day, arranged by one of our amazing supporters and Network Rail. We are grateful to our volunteers and team members that helped make the day a huge success, with music from The Glasgow Rock Choir and various performers throughout the day helping attract lots of attention. Information was shared with commuters and visitors to the station, with a collection of generous donations.

2. Campaign and lobby the government and key stakeholders for change to advance the standard of healthcare for individuals affected by pancreatic cancer.

As a small charity, we punch well above our weight when influencing governments and campaigning to win changes that will improve early diagnosis and save lives. Since launching a new campaigning and influencing strategy in 2021 we have seen significant steps forward in all Four Nations to improve early diagnosis.

Early in 2023, we worked with a number of bodies to submit proposals to the **National Cancer Board** that would take further innovative steps to improve early diagnosis of pancreatic cancer in England. These proposals included:

- Expanding Targeted Lung Health Checks to cover Pancreatic Cancer - At risk cohorts will be offered an extra scan of the area covering the kidney and pancreas and it only adds 10 -15 seconds to the procedure.
- Pancreatic Cancer Surveillance Coordinators to meet NG85 NICE guidance. - 10% of cases are linked to genetic risk factors. Coordinators will implement high-risk surveillance protocol to identify these people and enrol them on annual surveillance
- New case finding protocol for pancreatic cancer in patients with New Onset Diabetes and weight loss. - A new algorithm to identify these patients faster and speed up diagnosis
- Enable direct referrals into urgent cancer pathways and/or testing from a centralised service (such as NHS 111)
- Cutting the strain on Primary Care, this is an additional route to diagnosis for those with a combination of 'vague' and 'non-descript' symptoms.

We were very pleased when the National Cancer Board adopted all of these proposals and at the time of writing these projects are in the process of being piloted. As an organisation, we have continued to be heavily involved in shaping and delivering some of these projects including the new case-finding protocol for pancreatic cancer patients with new onset diabetes and weight loss. We have worked with NHS England and the University of Surrey to develop this project, identify partners, and create a pilot before any further rollout across England. We have met as a group once every four to six weeks so we can manage the progress and ensure there are no delays in getting this up and running.

We've continued to seek to change the key areas of our healthcare system to improve support and care for pancreatic cancer patients. One way we do this is through submitting consultation responses to governments and public bodies. In 2023 this included but was not limited to responses to the **National Cancer Strategy for England** (now the major conditions strategy) the **Scottish Cancer Strategy and Action Plan** and the **NICE suspected cancer consultation**. Our consultation responses resulted in governments adopting new proposals to improve early diagnosis of pancreatic cancer. For example, included in the Scottish Cancer Action Plan published alongside the final strategy it included a commitment to exploring the ways community pharmacists can support the diagnosis of cancer. This has long been an area of work for Pancreatic Cancer Action and was a key part of our submission to the strategy consultation.

In order to advance and promote our policy proposals in Scotland that had already been adopted in England, we attended the **Scottish Conservative Party conference** and the **Scottish Labour Party conference** in the spring. (There was no spring SNP Conference). Members of the team met with MSPs, MPs and councillors to explain the priorities of Pancreatic Cancer Action and why we needed to take action to improve the survival rate of pancreatic cancer. During the conferences, we also asked politicians to help us raise awareness of pancreatic cancer symptoms within their communities.

PANCREATIC CANCER ACTION

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

Throughout the year we networked and promoted our policy proposals to politicians and health leaders across the UK. In the run-up to the **annual Pancreatic Cancer Awareness Month debate at the Scottish Parliament**, we provided briefings to all MSPs on the key issues patients and their families face in Scotland and our proposals to improve early diagnosis and save lives. We also offered MSPs the opportunity to meet with a member of the team and our supporters.

As a charity, we attended the annual **Scottish Cancer Conference**. The conference allows us an opportunity to speak directly with health leaders and promote our accredited education and training for healthcare professionals as well as sharing our priorities for patients. Coming out of the conference it was clear that there is growing support within the wider healthcare community for some of the proposals we're putting forward to improve early diagnosis and save lives.

We continue to **work in partnership** with the Scottish Cancer Coalition, the Less Survivable Cancers Taskforce, the North Cancer Alliance (Scotland), CanCern (North East England), Cancer 52, One Cancer Voice and a number of other coalitions of cancer charities. This partnership working strengthens our voice and makes sure that patients' voices are put at the heart of decision-making by politicians and governments.

We continue to be a key partner in the delivery of The **SHPBN Pathway Improvement Project** (now called SCOT-HPB). This is delivered by the Scottish Government, NHS Scotland, and cancer charities and partners such as ourselves. Pancreatic Cancer Action have been leading on the patient and public involvement aspect of the project that is already seeing results and reducing the time from suspicion to treatment and care for pancreatic cancer patients.

3. Train and provide pioneering educational resources for our medical and healthcare communities.

Pancreatic Cancer Action provides **accredited e-learning for GPs, Pharmacists and Pharmacy Teams**. Our GP e-learning, hosted by The Royal College of General Practitioners (RCGP) was updated during the year. Various webinars were hosted with networks including members of RCGP Wales and The Wessex Cancer Alliance. We continue to provide GP and Pharmacy packs across the UK and thank our community of volunteers who help disseminate information on our resources in their local communities.

4. Innovative research - we fund it, we support it - to improve early diagnosis and develop effective treatments to improve pancreatic cancer outcomes.

As a small charity with limited funds, we are not able to invest millions into research, the same as larger organisations. However, by also being a small charity we are able to be more innovative and invest, kickstart, pump prime and support research that has the potential to save lives that might have been looked over by other organisations and much larger funders.

In anticipation of relaunching our **Early Diagnostic Challenge Award** in 2024, Pancreatic Cancer Action rejoined The Association of Medical Research Charities also known as The AMRC. The association provides support and advice to charities such as our own when making research grant awards. Since rejoining the association, staff members have partaken in AMRC hosted training to prepare us for the relaunch of the early diagnostic challenge award in 2024.

We continued to be an active partner in the research project we previously funded with a **University of Surrey** research team led by Dr Agnieszka Lemanska. The aims of the study were to confirm the link between diabetes and pancreatic cancer and to examine the differences in diabetes management and primary care presentation between patients who go on to develop pancreatic cancer and those who do not. The project was a retrospective case-control study, interrogating the RCGP database to provide a large sample size of cases and controls. Multiple variables can be examined from demographics to diagnostics, number of presentations at primary care to disease management. The project involves examining the GP records of patients with diabetes who went on to develop pancreatic cancer and those who did not develop the disease. Records will be taken from the RCGP database where approximately 9.5 million patients' data are stored. This allows a large sample of patients to be investigated. We have now supported the next stages of the research as we take its findings and implement the new case-finding protocol mentioned above. Pancreatic Cancer Action have been key in leading the patient and public involvement aspect of this work and making sure patients' voices are at the heart of the decision-making process. In order to continue to support this research the team at Pancreatic Cancer Action has supported **continuing funding applications** from the University of Surrey to ensure our seed-funded research has an even bigger impact.

PANCREATIC CANCER ACTION

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

Members of the team attended the **Prevention Research Conference** in Edinburgh and were able to speak to academics, scientists, health leaders and politicians about our research and the impact it has had so far. It was also an opportunity to inform partners about the plans to relaunch the Early Diagnostic Challenge Award.

5. Offer the provision of practical and emotional support and information to all affected by pancreatic cancer.

One of the key ways we offer support to patients and their families is through our **patient and health information booklets**. Our booklets cover a wide range of topics to ensure that patients and their families are getting the support and advice they need. These booklets are provided free of charge and are regularly ordered by both individuals and organisations such as hospitals and cancer centres. 2023 saw a 33% increase in the demand for our patient and health information booklets. This meant we were reaching more people than ever before with our accredited high-quality support information. Each one of the booklets is independently assessed and accredited by the Patient Information Forum and reviewed by highly trained medical professionals. The booklets are also complemented by our groundbreaking **recipe book**, which continues to be in high demand amongst patients and also continues to be provided free of charge thanks to the generous support of our donors.

We continue to look at how we can expand our offer and range of support for patients and their families going through an incredibly difficult time. One way in which we are looking to ensure comprehensive coverage of support information is through the creation of new patient and health information booklets. As a result, 2023 saw a **new genetics booklet** and a **new booklet for patients and carers** begin production. Creating new world-class accredited health information is a long process due to the need to involve and consult medical professionals peer reviewers, lay reviewers, patients and their families, health leaders and other charitable organisations. However, this process is necessary to ensure we can provide the best possible support to the people who need us most.

One of the key and most practical ways we can offer support to patients is through the funding we provide for a **Clinical Nurse Specialist** based at Glasgow Royal Infirmary. Our supporters' fundraising has enabled this post since 2019 and since then they have supported hundreds of individuals, patients, family members, colleagues and members of the public through their work. 2023 began with a new person being appointed to the role and as part of the Pancreatic Clinical Nurse Specialist team at Glasgow Royal Infirmary, they help to support over 230 patients per year. This workload includes interactions with patients in environments such as outpatient clinics, endoscopy, ward inpatient areas and telephone clinics. The Pancreatic Clinical Nurse Specialist team at Glasgow Royal Infirmary has over 2,500 interactions with patients every year across their work at return clinics, weekly consultant clinics, and weekly nurse-led clinics.

In 2023 we hosted our first "Purple Hearts Gathering" in Glasgow, providing a relaxed afternoon for our wonderful community of supporters, volunteers and staff to engage and connect during November's Pancreatic Cancer Awareness Month.

Fundraising

In 2023, income was generated through a wide range of fundraising activities and donations, including our amazing supporters taking part in challenge events, hosting fundraising activities in their communities and incredible support from corporates.

A significant event in the year was the Just Employment Law Summer Ball raising over £120,000 in June 2023. We are forever grateful for their ongoing support and charity partnership with Pancreatic Cancer Action.

Substantial legacies were bequeathed to our charity in 2023 and we value the kind generosity of people affected by pancreatic cancer.

We are continually inspired by the energy, enthusiasm and commitment of our supporters who are determined to change the pancreatic cancer story and save more lives through early diagnosis.

From dress down days in schools and workplaces, cake stalls, coffee mornings, bingo nights, charity dances, golf days, to distance challenges running, walking, swimming and climbing, our supporters continually put the fun into fundraising and embracing the colour purple, to help raise awareness and funds for pancreatic cancer. THANK YOU – we are so grateful for all you do.

PANCREATIC CANCER ACTION

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

Trusts and grants

We are very grateful to the many funders that give so generously towards our initiatives, activities and projects. In 2023 these included £5,000 of unrestricted grants and £57,260 of restricted grants.

Financial review

The results for the year are summarised in the Statement of Financial Activities on page 15.

The Trustees are pleased to report that the charity's incoming resources for 2023 amounted to £752,504 (2022: £488,089), (2021: £754,217), (2020: £1,256,477; an exceptional year which included a one-off transfer of £607,560 due to the merger with Pancreatic Cancer Scotland and £58,781 through the Coronavirus Job Retention Scheme) (2019: £786,505), (2018: £892,851), (2017: £757,812).

The Trustees would like to thank all those volunteers, fundraisers and donors - corporate, trusts and foundations, as well as individual donors who have supported the charity over the past years and upon whom we are dependent.

Total spending on charitable activities was £465,441 (2022: £450,195), (2021: £513,874), (2020: £437,838) (2019: £609,931) (2018: £669,187), (2017: £669,077).

The charity achieved a net loss for the year of -£8,077 (2022: £-241,741), (2021: £-87,740), (2020: £510,025) (2019: £-115,305) (2018: £-24,634) (2017: £-169,315).

Reserves policy

It is the policy of the charity that unrestricted funds which have not been designated for a specific use should be maintained to cover at least 6 months of operating expenditure. The Trustees consider that reserves at this level will ensure that, in the event of a significant drop in funding, they will be able to continue the charity's current activities while consideration is given to ways in which additional funds may be raised.

At 31st December 2023, the charity held reserves of £592,379 of which £283,789 was restricted. Free reserves stood at £308,590 which is in line with the level of the reserves policy established by the board.

Structure, governance and management

The charity is a company limited by guarantee, incorporated in June 2010, and is therefore governed by its Memorandum and Articles of Association. Its company registration number is 07272699 and its charity numbers are 1137689 (England and Wales) and SC049777 (Scotland).

The Trustees, who are also the directors for the purpose of company law, and who served during the year and up to the date of signature of the financial statements were:

H Matthews	(Resigned 17 March 2024)
N Menezes	
N Mumford	(Resigned 18 March 2024)
S Krag	(Resigned 23 May 2023)
H Goodfellow	(Resigned 12 June 2024)
L Condron	(Resigned 15 July 2024)
D Georgiou	(Resigned 2 July 2023)
R Legg	
C Carter	
E Cowan	
N Longworth	
L Nylander	
G Codacci Pisanelli	(Appointed 18 March 2024)
D Slater	(Appointed 18 March 2024)
G Lesca	(Appointed 18 March 2024)

PANCREATIC CANCER ACTION

TRUSTEES' REPORT (INCLUDING DIRECTORS' REPORT) (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

None of the Trustees has any beneficial interest in the charity. The members of the company guarantee to contribute £10 in the event of liquidation.

The Trustees continue to keep the Charity's activities under review, particularly with regard to any major physical or financial risks that may arise from time to time, and to monitor the effectiveness of the system of internal controls and other variable means, including insurance cover where appropriate, by which those risks already identified by the Trustees can be mitigated.

Statement of Trustees' responsibilities

The Trustees, who are also the directors of Pancreatic Cancer Action for the purpose of company law, are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company Law requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that year.

In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in operation.

The Trustees are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and the Charities Accounts (Scotland) Regulations 2006 (as amended). They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Auditor

In accordance with the company's articles, a resolution proposing that Alliotts LLP be reappointed as auditor of the company will be put at a General Meeting.

The Trustees' report was approved by the Board of Trustees.

giulio codacci-pisanelli
giulio.codacci-pisanelli (Sep 23, 2024 17:02 GMT+1)

G Codacci Pisanelli

Chair of Trustees

Dated: 23/09/2024.....

PANCREATIC CANCER ACTION

INDEPENDENT AUDITOR'S REPORT

TO THE TRUSTEES OF PANCREATIC CANCER ACTION

Opinion

We have audited the financial statements of Pancreatic Cancer Action (the 'charity') for the year ended 31 December 2023 which comprise the statement of financial activities, the balance sheet, the statement of cash flows and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 *The Financial Reporting Standard applicable in the UK and Republic of Ireland* (United Kingdom Generally Accepted Accounting Practice).

In our opinion, the financial statements:

- give a true and fair view of the state of the charitable company's affairs as at 31 December 2023 and of its incoming resources and application of resources, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and regulation 8 of the Charities Accounts (Scotland) Regulations 2006 (as amended).

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the *Auditor's responsibilities for the audit of the financial statements* section of our report. We are independent of the charity in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the Trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charity's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the Trustees with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. The Trustees are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

PANCREATIC CANCER ACTION

INDEPENDENT AUDITOR'S REPORT (CONTINUED)

TO THE TRUSTEES OF PANCREATIC CANCER ACTION

Matters on which we are required to report by exception

We have nothing to report in respect of the following matters in relation to which the Charities (Accounts and Reports) Regulations 2008 and the Charities Accounts (Scotland) Regulations 2006 (as amended) require us to report to you if, in our opinion:

- the information given in the financial statements is inconsistent in any material respect with the Trustees' report; or
- sufficient and proper accounting records have not been kept; or
- the financial statements are not in agreement with the accounting records; or
- we have not received all the information and explanations we require for our audit.

Responsibilities of Trustees

As explained more fully in the statement of Trustees' responsibilities, the Trustees, who are also the directors of the charity for the purpose of company law, are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the Trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. In preparing the financial statements, the Trustees are responsible for assessing the charity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

We have been appointed as auditor under section 144 of the Charities Act 2011 and section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005 and report in accordance with the Acts and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.

Extent to which the audit was considered capable of detecting irregularities, including fraud

Our approach to identifying and assessing the risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, was as follows:

- the engagement partner ensured that the engagement team collectively had the appropriate competence, capabilities and skills to identify or recognise non-compliance with applicable laws and regulations;
- we identified the laws and regulations applicable to the company through discussions with Trustees and other management, and from our knowledge and experience of the sector;
- we focused on specific laws and regulations which we considered may have a direct material effect on the financial statements or the operations of the charitable company, including the Companies Act 2006, the Charities Act 2011, the Charities SORP, taxation legislation, data protection, anti-bribery, employment, environmental and health and safety legislation;
- we assessed the extent of compliance with the laws and regulations identified above through making enquiries of management and inspecting legal correspondence; and
- identified laws and regulations were communicated within the audit team regularly and the team remained alert to instances of non-compliance throughout the audit.

PANCREATIC CANCER ACTION

INDEPENDENT AUDITOR'S REPORT (CONTINUED) TO THE TRUSTEES OF PANCREATIC CANCER ACTION

We assessed the susceptibility of the charitable company's financial statements to material misstatement, including obtaining an understanding of how fraud might occur, by:

- making enquiries of management as to where they considered there was susceptibility to fraud, their knowledge of actual, suspected and alleged fraud; and
- considering the internal controls in place to mitigate risks of fraud and non-compliance with laws and regulations.

Audit response to risks identified

To address the risk of fraud through management bias and override of controls, we:

- performed analytical procedures to identify any unusual or unexpected relationships;
- reviewed all transactions listed;
- assessed whether judgements and assumptions made in determining the accounting estimates were indicative of potential bias; and
- investigated the rationale behind significant or unusual transactions.

In response to the risk of irregularities and non-compliance with laws and regulations, we designed procedures which included, but were not limited to:

- agreeing financial statement disclosures to underlying supporting documentation; and
- enquiring of management as to actual and potential litigation and claims.

There are inherent limitations in our audit procedures described above. The more removed that laws and regulations are from financial transactions, the less likely it is that we would become aware of non-compliance. Auditing standards also limit the audit procedures required to identify non-compliance with laws and regulations to enquiry of the Trustees and other management and the inspection of regulatory and legal correspondence, if any.

Material misstatements that arise due to fraud can be harder to detect than those that arise from error as they may involve deliberate concealment or collusion.

A further description of our responsibilities is available on the Financial Reporting Council's website at: <https://www.frc.org.uk/auditorsresponsibilities>. This description forms part of our auditor's report.

Other matters which we are required to address

In the previous accounting period, the trustees took advantage of audit exemption under s477 of the Companies Act. Therefore, the comparative figures in respect of the prior period to 31 December 2022 were not subject to audit.

This report is made solely to the company's members, as a body, in accordance with section 391 of the Companies Act 2014. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.



Stephen Meredith BA FCA DChA (Senior Statutory Auditor)
for and on behalf of Alliotts LLP

23/09/2024
.....

Chartered Accountants
Statutory Auditor

3 London Square
Cross Lanes
Guildford
GU1 1UJ

Alliotts LLP is eligible for appointment as auditor of the charity by virtue of its eligibility for appointment as auditor of a company under section 1212 of the Companies Act 2006.

PANCREATIC CANCER ACTION

STATEMENT OF FINANCIAL ACTIVITIES INCLUDING INCOME AND EXPENDITURE ACCOUNT

FOR THE YEAR ENDED 31 DECEMBER 2023

		Unrestricted funds 2023 £	Restricted funds 2023 £	Total 2023 £	Unrestricted funds 2022 £	Restricted funds 2022 £	Total 2022 £
	Notes						
<u>Income from:</u>							
Donations and legacies	3	571,774	170,357	742,131	463,769	18,474	482,243
Other trading activities	4	3,334	-	3,334	4,691	-	4,691
Investments	5	7,039	-	7,039	1,155	-	1,155
Total income		<u>582,147</u>	<u>170,357</u>	<u>752,504</u>	<u>469,615</u>	<u>18,474</u>	<u>488,089</u>
<u>Expenditure on:</u>							
Raising funds	6	276,495	18,645	295,140	279,635	-	279,635
Charitable activities	7	288,539	176,902	465,441	322,026	128,169	450,195
Total expenditure		<u>565,034</u>	<u>195,547</u>	<u>760,581</u>	<u>601,661</u>	<u>128,169</u>	<u>729,830</u>
Gross transfers between funds	17	-	-	-	56,213	(56,213)	-
Net income/(expenditure) for the year/							
Net movement in funds		17,113	(25,190)	(8,077)	(75,833)	(165,908)	(241,741)
Fund balances at 1 January 2023		<u>291,477</u>	<u>308,979</u>	<u>600,456</u>	<u>367,310</u>	<u>474,887</u>	<u>842,197</u>
Fund balances at 31 December 2023		<u>308,590</u>	<u>283,789</u>	<u>592,379</u>	<u>291,477</u>	<u>308,979</u>	<u>600,456</u>

The statement of financial activities includes all gains and losses recognised in the year. All income and expenditure derive from continuing activities.

The statement of financial activities also complies with the requirements for an income and expenditure account under the Companies Act 2006.

PANCREATIC CANCER ACTION

BALANCE SHEET

AS AT 31 DECEMBER 2023

	Notes	2023 £	£	2022 £	£
Fixed assets					
Tangible assets	12		-		364
Current assets					
Stocks	13	3,675		3,875	
Debtors falling due after one year	14	333		2,333	
Debtors falling due within one year	14	78,865		72,275	
Cash at bank and in hand		545,716		584,729	
		628,589		663,212	
Creditors: amounts falling due within one year	15	(36,210)		(63,120)	
Net current assets			592,379		600,092
Total assets less current liabilities			592,379		600,456
The funds of the charity					
Restricted income funds	17		283,789		308,979
Unrestricted funds			308,590		291,477
			592,379		600,456

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the Trustees on 23/09/2024

giulio codacci-pisanelli
giulio.codacci-pisanelli (Sep 23, 2024 17:02 GMT+1)

G Codacci Pisanelli
Chair of Trustees

Company registration number 07272699 (England and Wales)

PANCREATIC CANCER ACTION

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023

1 Accounting policies

Charity information

Pancreatic Cancer Action is a registered charity and a company incorporated by guarantee with no share capital, exempted under section 5 of the Companies Act 2006 from the requirement to use "Limited" as part of its name. It is incorporated in England and Wales under registration number 07272699 and its registered office is Suite 3.10 Covault, Fullarton Road, Cambuslang, Glasgow, G32 8YL.

1.1 Accounting convention

The financial statements have been prepared in accordance with the charity's Statement of Recommended Practice applicable to charities preparing accounts with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102), the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005, the Charities Accounts (Scotland) Regulations 2006 (as amended), FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" ("FRS 102") and the Charities SORP "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (effective 1 January 2019). The charity is a Public Benefit Entity as defined by FRS 102.

The financial statements are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, [modified to include the revaluation of freehold properties and to include investment properties and certain financial instruments at fair value]. The principal accounting policies adopted are set out below.

1.2 Going concern

At the time of approving the financial statements, the Trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the Trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3 Charitable funds

Unrestricted funds are available for use at the discretion of the Trustees in furtherance of their charitable objectives.

Restricted funds are subject to specific conditions by donors or grantors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the financial statements.

1.4 Income

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Legacies are recognised on receipt or otherwise if the charity has been notified of an impending distribution, the amount is known, and receipt is expected. If the amount is not known, the legacy is treated as a contingent asset.

Gifts of assets and services are recognised at market value to the charity.

PANCREATIC CANCER ACTION

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

1 Accounting policies

(Continued)

1.5 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement, and the amount of the obligation can be measured reliably.

Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges are allocated on the portion of the asset's use.

Expenditure has been allocated between the main headings in the Statement of Financial Activities on the basis of the type of activity to which they relate, including irrecoverable V.A.T.

Income and expenses have not been netted off.

1.6 Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Fixtures, fittings & equipment	25% on cost
Computers	25% on cost

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in the statement of financial activities.

1.7 Impairment of fixed assets

At each reporting end date, the charity reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any).

1.8 Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition. Items held for distribution at no or nominal consideration are measured the lower of replacement cost and cost.

The charity are recognising 80% of the stock as free stock issues to support activities raising funds and awareness. The balance recognised on the balance sheet is the residual value of the stock.

Net realisable value is the estimated selling price less all estimated costs of completion and costs to be incurred in marketing, selling and distribution.

1.9 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

PANCREATIC CANCER ACTION

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

1 Accounting policies

(Continued)

1.10 Financial instruments

The charity has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the charity's balance sheet when the charity becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Basic financial liabilities

Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of operations from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Derecognition of financial liabilities

Financial liabilities are derecognised when the charity's contractual obligations expire or are discharged or cancelled.

1.11 Employee benefits

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

Termination benefits are recognised immediately as an expense when the charity is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.12 Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

PANCREATIC CANCER ACTION

STATEMENT OF CASH FLOWS

FOR THE YEAR ENDED 31 DECEMBER 2023

	Notes	2023 £	£	2022 £	£
Cash flows from operating activities					
Cash absorbed by operations	22		(46,052)		(239,155)
Investing activities					
Investment income received		7,039		1,155	
		<u>7,039</u>		<u>1,155</u>	
Net cash generated from investing activities			7,039		1,155
Net cash used in financing activities			-		-
			<u>-</u>		<u>-</u>
Net decrease in cash and cash equivalents			(39,013)		(238,000)
Cash and cash equivalents at beginning of year			584,729		822,729
			<u>584,729</u>		<u>822,729</u>
Cash and cash equivalents at end of year			<u>545,716</u>		<u>584,729</u>

PANCREATIC CANCER ACTION

STATEMENT OF CASH FLOWS (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2023

2 Critical accounting estimates and judgements

In the application of the charity's accounting policies, the Trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

3 Donations and legacies

	Unrestricted funds	Restricted funds	Total Unrestricted funds	Restricted funds	Total
	2023 £	2023 £	2023 £	2022 £	2022 £
Donations and gifts	544,215	14,539	558,754	463,769	18,474
Legacies receivable	22,559	98,558	121,117	-	-
Grants receivable for core activities	5,000	57,260	62,260	-	-
	<u>571,774</u>	<u>170,357</u>	<u>742,131</u>	<u>463,769</u>	<u>18,474</u>

4 Other trading activities

	Unrestricted funds	Unrestricted funds
	2023 £	2022 £
Sales of merchandise	<u>3,334</u>	<u>4,691</u>

5 Income from investments

	Unrestricted funds	Unrestricted funds
	2023 £	2022 £
Interest receivable	<u>7,039</u>	<u>1,155</u>

PANCREATIC CANCER ACTION

STATEMENT OF CASH FLOWS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

6 Raising funds

	Unrestricted funds	Restricted funds	Total	Total
	2023 £	2023 £	2023 £	2022 £
<u>Fundraising and publicity</u>				
Fundraising costs	91,592	-	91,592	84,797
Staff costs	152,271	15,934	168,205	139,222
Depreciation and impairment	137	-	137	1,042
Support costs	26,603	2,711	29,314	34,427
	<u>270,603</u>	<u>18,645</u>	<u>289,448</u>	<u>259,488</u>
<u>Trading costs</u>				
Other trading activities	5,893	-	5,893	20,147
	<u>276,495</u>	<u>18,645</u>	<u>295,140</u>	<u>279,635</u>

7 Charitable activities

	Raising awareness	Supporting research	Medical education	Patient support/information	Total 2023	Total 2022
	2023 £	2023 £	2023 £	2023 £	£	£
Staff costs	158,002	17,798	35,354	42,988	254,142	240,105
Depreciation and impairment	143	16	32	36	227	1,711
Other costs	100,840	11,360	22,564	27,431	162,195	151,855
	<u>258,985</u>	<u>29,174</u>	<u>57,950</u>	<u>70,458</u>	<u>416,567</u>	<u>393,671</u>
Share of support costs (see note 9)	25,084	2,826	5,613	6,828	40,351	50,932
Share of governance costs (see note 9)	5,301	597	1,186	1,442	8,526	5,592
	<u>289,370</u>	<u>32,597</u>	<u>64,749</u>	<u>78,725</u>	<u>465,441</u>	<u>450,195</u>
Analysis by fund						
Unrestricted funds	205,911	14,364	37,191	31,073	288,539	322,026
Restricted funds	83,459	18,233	27,558	47,652	176,902	128,169
	<u>289,370</u>	<u>32,597</u>	<u>64,749</u>	<u>78,725</u>	<u>465,441</u>	<u>450,195</u>

PANCREATIC CANCER ACTION

STATEMENT OF CASH FLOWS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

7 Charitable activities

(Continued)

For the year ended 31 December 2022

	Raising awareness	Supporting research	Medical education	Patient support/information	Total 2022
	£	£	£	£	£
Staff costs	188,938	3,839	18,338	28,990	240,105
Depreciation and impairment	1,346	27	131	207	1,711
Other costs	119,338	2,391	12,070	18,056	151,855
	<u>309,622</u>	<u>6,257</u>	<u>30,539</u>	<u>47,253</u>	<u>393,671</u>
Share of support costs (see note 9)	40,079	814	3,890	6,149	50,932
Share of governance costs (see note 9)	4,401	89	427	675	5,592
	<u>354,102</u>	<u>7,160</u>	<u>34,856</u>	<u>54,077</u>	<u>450,195</u>
Analysis by fund					
Unrestricted funds	253,382	4,620	32,316	31,708	322,026
Restricted funds	100,720	2,540	2,540	22,369	128,169
	<u>354,102</u>	<u>7,160</u>	<u>34,856</u>	<u>54,077</u>	<u>450,195</u>

8 Trustees

None of the Trustees (or any persons connected with them) received any remuneration during the year and none of them were reimbursed travelling expenses (2022- £Nil).

PANCREATIC CANCER ACTION

STATEMENT OF CASH FLOWS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

9 Support costs

	Support costs £	Governance costs £	2023 £	Support costs £	Governance costs £	2022 £
Rent	22,268	-	22,268	18,941	-	18,941
Office costs	2,841	-	2,841	6,378	-	6,378
Telephone costs	3,140	-	3,140	2,272	-	2,272
Computer costs	24,718	-	24,718	17,303	-	17,303
Insurance	3,029	-	3,029	2,496	-	2,496
Training, recruitment and internship costs	5,196	-	5,196	31,400	-	31,400
Book-keeping and Accountancy	2,885	-	2,885	2,587	-	2,587
Bank charges	474	-	474	572	-	575
Audit fees	-	10,400	10,400	-	5,760	5,760
Legal and professional	-	3,240	3,240	-	3,240	3,240
	<u>64,551</u>	<u>13,640</u>	<u>78,191</u>	<u>81,952</u>	<u>9,000</u>	<u>90,952</u>
Analysed between						
Fundraising	24,200	5,114	29,314	31,020	3,408	34,428
Charitable activities	40,351	8,526	48,877	50,932	5,592	56,524
	<u>64,551</u>	<u>13,640</u>	<u>78,191</u>	<u>81,952</u>	<u>9,000</u>	<u>90,952</u>

Governance costs include payments of £7,800 (2022 - £5,760 for independent examination fees) for audit fees and £2,600 for accounts preparation fees.

10 Employees

The average monthly number of employees during the year was:

	2023 Number	2022 Number
	13	11
Employment costs	2023 £	2022 £
Wages and salaries	380,476	339,477
Social security costs	32,403	29,650
Other pension costs	9,468	10,200
	<u>422,347</u>	<u>379,327</u>

There were no employees whose annual remuneration was more than £60,000.

PANCREATIC CANCER ACTION

STATEMENT OF CASH FLOWS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

11 Taxation

The company is a registered charity and is, therefore, exempt from taxation on its charitable activities.

12 Tangible fixed assets

	Fixtures, fittings & equipment £	Computers £	Total £
Cost			
At 1 January 2023	10,612	12,245	22,857
At 31 December 2023	10,612	12,245	22,857
Depreciation and impairment			
At 1 January 2023	10,329	12,164	22,493
Depreciation charged in the year	283	81	364
At 31 December 2023	10,612	12,245	22,857
Carrying amount			
At 31 December 2023	-	-	-
At 31 December 2022	283	81	364

13 Stocks

	2023 £	2022 £
Finished goods and goods for resale	3,675	3,875

14 Debtors

Amounts falling due within one year:	2023 £	2022 £
Other debtors	-	12,076
Prepayments and accrued income	78,865	60,199
	78,865	72,275
Amounts falling due after more than one year:	2023 £	2022 £
Prepayments and accrued income	333	2,333
Total debtors	79,198	74,608

PANCREATIC CANCER ACTION

STATEMENT OF CASH FLOWS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

15 Creditors: amounts falling due within one year

	2023 £	2022 £
Other taxation and social security	10,010	8,528
Trade creditors	7,916	29,399
Accruals and deferred income	18,284	25,193
	<u>36,210</u>	<u>63,120</u>

16 Retirement benefit schemes

	2023 £	2022 £
Defined contribution schemes		
Charge to profit or loss in respect of defined contribution schemes	9,468	10,200
	<u>9,468</u>	<u>10,200</u>

The charity operates a defined contribution pension scheme for all qualifying employees. The assets of the scheme are held separately from those of the charity in an independently administered fund.

17 Restricted funds

The restricted funds of the charity comprise the unexpended balances of donations and grants held on trust subject to specific conditions by donors as to how they may be used.

	At 1 January 2023 £	Incoming resources £	Resources expended £	Transfers £	At 31 December 2023 £
Pat & Paul	12,605	8,584	-	-	21,189
POW app	17,200	-	-	-	17,200
Recipe Book	14,335	1,000	(4,690)	-	10,645
Patient Information Booklets	8,357	7,955	(16,312)	-	-
NIPanC	5,845	-	-	-	5,845
Translation of resources	-	2,000	(1,507)	-	493
Research	-	22,500	-	-	22,500
Pancreatic Cancer Scotland	247,677	98,558	(171,039)	-	175,196
PC Aware North East England	-	20,000	-	-	20,000
Action on the Ground Glasgow Project	-	9,760	-	-	9,760
Community volunteers	960	-	-	-	960
GP Packs	2,000	-	(2,000)	-	-
	<u>308,979</u>	<u>170,357</u>	<u>(195,548)</u>	<u>-</u>	<u>283,788</u>

PANCREATIC CANCER ACTION

STATEMENT OF CASH FLOWS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

17 Restricted funds

(Continued)

Previous year:	At 1 January 2022	Incoming resources	Resources expended	Transfers	At 31 December 2022
	£	£	£	£	£
Pat & Paul	2,506	10,099	-	-	12,605
POW app	17,200	-	-	-	17,200
Recipe Book	18,174	-	(3,839)	-	14,335
Patient Information Booklets	15,972	8,375	(15,990)	-	8,357
Hope is Contagious	156	-	(156)	-	-
NIPanC	6,456	-	(611)	-	5,845
Pancreatic Cancer Scotland	411,463	-	(107,573)	(56,213)	247,677
Community volunteers	960	-	-	-	960
GP Packs	2,000	-	-	-	2,000
	<u>474,887</u>	<u>18,474</u>	<u>(128,169)</u>	<u>(56,213)</u>	<u>308,979</u>

Restricted funds relate to grants received for the specific purposes as set out above. Any amount unspent is carried forward to be spent in the next financial year.

No transfer between unrestricted and restricted funds has been made in the year ended 31 December 2023.

18 Analysis of net assets between funds

	Unrestricted funds 2023 £	Restricted funds 2023 £	Total 2023 £
At 31 December 2023:			
Current assets/(liabilities)	308,590	283,789	592,379
	<u>308,590</u>	<u>283,789</u>	<u>592,379</u>
	Unrestricted funds 2022 £	Restricted funds 2022 £	Total 2022 £
At 31 December 2022:			
Tangible assets	364	-	364
Current assets/(liabilities)	291,113	308,979	600,092
	<u>291,477</u>	<u>308,979</u>	<u>600,456</u>

PANCREATIC CANCER ACTION

STATEMENT OF CASH FLOWS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

19 Financial commitments, guarantees and contingent liabilities

To date, the charity has received £46,897 in donations from solicitors relating to old monies held in client accounts which they have not been able to return. There is a possibility that in the future the clients in question could still return for these monies and, as such, the charity has agreed to refund part of the donation if this occurs. No provision has been made in these financial statements for any possible refund as the likelihood is remote and cannot be quantified.

The charity has committed to sponsor a nursing post within NHS Greater Glasgow & Clyde (GGC) for a three year period which started in January 2023. The total commitment over the next two years is expected to be £90,238

20 Operating lease commitments

Lessee

Operating lease payments in the prior year related to office lease rental. The charity moved to new premises in the current year using licence agreements which provide shorter, more flexible terms.

At the reporting end date the charity had outstanding commitments for future minimum lease payments under non-cancellable operating leases, which fall due as follows:

	2023 £	2022 £
Within one year	-	4,320
	<u> </u>	<u> </u>

21 Related party transactions

Remuneration of key management personnel

The remuneration of key management personnel is as follows.

	2023 £	2022 £
Aggregate compensation	58,599	56,393
	<u> </u>	<u> </u>

The key management personnel of the Charity is considered to be the CEO.

There were no other related party transactions.

PANCREATIC CANCER ACTION

STATEMENT OF CASH FLOWS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023

22	Cash generated from operations	2023 £	2022 £
	Deficit for the year	(8,077)	(241,741)
	Adjustments for:		
	Investment income recognised in statement of financial activities	(7,039)	(1,155)
	Depreciation and impairment of tangible fixed assets	364	2,753
	Movements in working capital:		
	Decrease in stocks	200	14,536
	(Increase) in debtors	(4,590)	(24,031)
	(Decrease)/increase in creditors	(26,910)	10,483
	Cash absorbed by operations	<u>(46,052)</u>	<u>(239,155)</u>
23	Analysis of changes in net funds		
	The charity had no material debt during the year.		